SCHEMBL276032

SCHEMBL276032

CSc1ccc(Oc2ccc(Cl)cc2C=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 10/20 0.57
SLC6A2 P23975 3/20 0.57
SLC6A3 Q01959 3/20 0.57
CYP1A2 P05177 3/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
LMNA P02545 2/20 0.42
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ERN1 O75460 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419953 0.83 ALDH1A1 (0.61) SLC6A4CYP1A2ALDH1A1CYP2C9CYP2C19
SCHEMBL19563733 0.80 EPAS1 (0.49) SLC6A4CYP1A2ALDH1A1CYP2C9CYP2C19
SCHEMBL12437522 0.80 PDE7A (0.56) CYP1A2ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL13815379 0.80 CYP1A2 (0.44) SLC6A4CYP1A2ALDH1A1CYP2C9CYP2C19
SCHEMBL23418697 0.80 LMNA (0.62) CYP1A2ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL30933708 0.80 LMNA (0.62) CYP1A2ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL6151339 0.78 ALDH1A1 (0.68) SLC6A4SLC6A2SLC6A3CYP1A2ALDH1A1
SCHEMBL5321372 0.77 NPSR1 (0.47) SLC6A4CYP1A2ALDH1A1CYP2C9CYP2C19
SCHEMBL276174 0.77 EPAS1 (0.46) SLC6A4CYP1A2ALDH1A1CYP2C9CYP2C19
SCHEMBL276668 0.77 MERTK (0.46) SLC6A4SLC6A3CYP1A2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT SLC6A4 2563/4885SLC6A2 3370/4885SLC6A3 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.